Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Trial end date:
2019-01-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are
resistant or intolerant to either dasatinib or nilotinib, or have the
(T)hreonine-315-(I)soleucine (T315I) mutation.